Mutations in PALB2 have been demonstrated in 1.1% of patients with familial breast cancer [29] and the c.1592delT frameshift mutation has been linked to a 6-fold increase in likelihood of developing breast cancer [30]. PALB2 mutations were also identified in 0.6% of patients with familial pancreatic cancer [31]. PALB2-deficient lymphoblasts EUFA1341 cells displayed increased cytotoxicity in response to Olaparib compared to their controls [28]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.